Shopping Cart
- Remove All
Your shopping cart is currently empty
Luxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $318 | In Stock | |
| 5 mg | $768 | In Stock | |
| 10 mg | $1,180 | In Stock | |
| 25 mg | $1,780 | In Stock | |
| 50 mg | $2,320 | In Stock | |
| 100 mg | $2,970 | In Stock |
| Description | Luxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. |
| Targets&IC50 | P-gp:> 5 μM (monolayer assay), BCRP:0.21 μM (vesicle assay), P-gp:0.23 μM (vesicle assay), BCRP:1.55 μM (monolayer assay) |
| In vivo | Luxdegalutamide (ARV-766) significantly and dose-dependently inhibits tumor growth in mouse LNCaP and VCaP xenograft models.[2] |
| Synonyms | ARV-766 |
| Molecular Weight | 807.95 |
| Formula | C45H54FN7O6 |
| Cas No. | 2750830-09-0 |
| Smiles | O([C@H]1C(C)(C)[C@H](NC(=O)C2=CC=C(C=C2)N3CCC(CN4CCN(CC4)C5=CC(F)=C(C(N[C@@H]6C(=O)NC(=O)CC6)=O)C=C5)CC3)C1(C)C)C7=CC(OC)=C(C#N)C=C7 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (309.43 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.